{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:44:17Z","timestamp":1782369857032,"version":"3.54.5"},"reference-count":19,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Checkpoint inhibition use before alloBMT followed by PTCy is not associated with increased aGvHD or transplant-related mortality\/morbidity. Prior checkpoint inhibitor therapy should not be a contraindication to allogeneic transplantation, especially in the setting of PTCy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018019208","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:56:01Z","timestamp":1536249361000},"page":"2226-2229","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide"],"prefix":"10.1182","volume":"2","author":[{"given":"Laura K.","family":"Schoch","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Imus","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levis","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"10","key":"2019111615561861200_B1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111615561861200_B2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","article-title":"Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation","volume":"131","author":"Soiffer","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111615561861200_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"key":"2019111615561861200_B4","unstructured":"Opdivo prescribing information.\n          https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s024lbl.pdf. Accessed 17 March 2017."},{"issue":"17","key":"2019111615561861200_B5","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111615561861200_B6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"2019111615561861200_B7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111615561861200_B8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2016.12.636","article-title":"Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors","volume":"23","author":"Carnevale-Schianca","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111615561861200_B9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111615561861200_B10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111615561861200_B11","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111615561861200_B12","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111615561861200_B13","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111615561861200_B14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111615561861200_B15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111615561861200_B16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2019111615561861200_B17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111615561861200_B18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019111615561861200_B19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/17\/2226\/881552\/advances019208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/17\/2226\/881552\/advances019208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T20:56:29Z","timestamp":1573937789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/17\/2226\/15846\/Immune-checkpoint-inhibitors-as-a-bridge-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,9,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018019208","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]}}}